

CannaTech Conference Tel Aviv 2019

mgc pharma 

*Leading the way in Cannabis derived Medicines with
a Seed to Pharma Strategy*

This presentation has been prepared by MGC Pharmaceuticals Limited ("Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

European focused Bio-Pharma company, developing a vertically integrated business through the whole Phytomedicines value chain - “Seed to Pharmacy” strategy

Capital Structure


ASX code	MXC
Market capitalisation (as at 31/03/2019)	~A\$42m
Share price (as at 31/03/2019)	3.5c
Cash at Bank (as at 31/12/2018)	~A\$6.9m

Issued Capital

Ordinary shares	1,212m
Listed Options (6.5c, expiring 30/6/19)	91.3m
Performance Rights	3.6m
Unlisted Options (12.5c, expiring 31/3/21)	19.9m
Unlisted Options (15.0c, expiring 30/6/21)	10.0m

Investors

- Management
- Key supporters
- Institutions
- Retail



Advisers

Lead Corporate Advisor: Chieftain Securities

Auditors

PKF Mack
Level 4,
35 Havelock Street,
West Perth WA 6005

Lawyers

Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan Street,
Perth WA 6000

- A European Bio-Pharma company with a “Seed to Pharmacy” strategy
- *Cost-effective, affordable, high-quality, standardised Cannabis derived medicines*
 - *3 Pharmaceuticals products in late-stage development*
 - *ASX listed since 2016*



Highly experienced team in the Bio-Pharma and Capital markets



Roby Zomer
Managing Director & Founder

Following 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, Mr. Zomer joined MGC Pharmaceuticals as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC's position as a leader in research and development, as well as ensuring top performance from our global operations.



Nativ Segev
Founder and Director

The founder of MGC Pharma, previously CEO of a Israeli licensed Medical Cannabis company, with over 10 years of experience in the global medical cannabis industry and over 15 years of experience in executive roles. Founded MGC Pharma to expand into the International markets and to raise the quality and viability of Medicinal Phyto-Cannabinoid products.



Brett Mitchell
Executive Chairman

With over 20 years of experience in the founding, financing and management of both private and publicly listed companies, Mr. Mitchell is responsible for the corporate strategy, capital markets and financial management of the company, and is integrally involved in assisting in building a new industry from the ground up in Australia.



Dr. Stephen Parker
Non Executive Director

Dr Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience focused on the pharmaceutical and biotechnology sectors in the UK, Europe and North America. Dr Parker is regarded as a leading corporate expert and strategic thinker. He has a reputation for rapid and clear analysis and the ability to translate this analysis into an implemented solution.



Dr. Ross Walker
Non Executive Director &
Head of Medical Advisory Board

Dr. Walker is a well-known figure in Australian health, as former host of a weekly radio program and a prominent cardiologist who specialises in echocardiography and preventative cardiology. Dr. Walker has published several books, and lectures both nationally and internationally. His contacts in the medical establishment and beyond allow him to facilitate relationships for MGC and draw positive public attention to the brand.

Strong Scientific team



Dr. Johnny Gruenfeld
Chief Scientific Officer

Professor Uri Kramer
Head of Neurology
Product Development

Professor David Neubauer

Assoc. Professor Wendyl D'Souza

Professor Stane Srčič

Certified in Israel, with clinical experience at the MD Andersen Cancer Center, [Prof]. Gruenfeld has spent the last twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cannabis as a treatment for oncological palliative care. Involved in the licensing of care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.

One of the few medical professionals in the world to have run full scale epilepsy trials with Cannabis, Dr. Kramer brings a wealth of experience in various fields (Neurology, Pediatric Neurology, Adolescent Psychology & Child Development). Additionally, Professor Kramer is a Former president of the Israeli League Against Epilepsy, giving him unique insight into the daily struggles of the patients his research benefits.

As Head of Department of Child, Adolescent and Developmental Neurology at University Children's Hospital, Ljubljana, Dr Neubauer is widely published and respected, and has dealt with children and adolescents in Neurological contexts for more than thirty years.

A world renowned Consultant Neurologist and Epileptologist with over 15 years' clinical experience researching new and emerging treatments for common neurological disorders within a rigorous scientific framework, Professor Wendyl D'Souza is an Associate Professor in Neuroepidemiology & Health Services Research in the Department of Medicine, St Vincent's Hospital, The University of Melbourne & Head of Epilepsy Services at St Vincent's Hospital.


Stane Srčič is a Professor of Pharmaceutics and Head of the Department of Pharmaceutics at the University of Ljubljana, where he held the position of Vice-Dean between 1996 and 2000. From 1987-88 he was Assistant and Associate Professor in Ljubljana before becoming a full Professor and taking on the role of Head of Department.

Global Cannabis Market 2028
US\$154.7Bn¹

Global Pharma Market 2028
US\$1,567Bn²

MGC Pharma aims to secure a significant share in the global Cannabis Pharmaceutical Market.

MGC Pharma targets large markets, where cannabis for medical uses is likely to have a high degree of success.



3 Pharmaceuticals products in late-stage development

1. Source: [Prohibition Partners Reports](#): the African Cannabis Report, the European Cannabis Report 3rd Edition, the LATAM Cannabis Report, the Oceania Cannabis Report
2. Source: [The Growing Pharmaceuticals Market: Expert Forecasts and Analysis](#) by The Business Research Company

In-House “Seed to Pharmacy” strategy supported by cutting-edge R&D ensures delivery of cost-effective, affordable, Cannabis based medicines

<p>Strong Cannabinoid-based products</p> <p>3 IMPs in late-stage development</p> <p>CannEpi™: drug-resistant epilepsy CogniCann™: Dementia treatment InCann™: Crohn’s Disease</p>	<p>Strong Leadership</p> <p>Experienced Board and Executive Management team, with more than 15 years accrued experience in phytocannabinoid research and patients treatment</p> <p>Prof Kramer, Dr. Johnny Gruenfeld and Prof Neubauer, have access to large clinical treatments data</p>	<p>World Class Assets</p> <p>World-class EU GMP certified production facility (Slovenia) for development and manufacturing (IMP) of Phytomedicines.</p> <p>Genetics and breeding research facilities with the Ljubljana University and Czech Republic’s Institute, fully licensed</p>
<p>Clear Pharma Strategy</p> <p>Advanced clinical program in Western Australia, Melbourne, Slovenia and Malta, EMA SME Approved</p> <p>Collaborating with global leading R&D institutes: RMIT, The Hebrew University, University of Sydney, University of Ljubljana, Educational program with EAA</p>	<p>Substantial Market Opportunity</p> <p>Global cannabis market is estimated to be worth +US\$154.7bn by 2028¹</p> <p>Emerging research continues to validate the significant medical application of cannabis</p>	<p>Geographically Scalable</p> <p>Multiple operational sites with Europe as center of R&D and production</p> <p>IP is transferrable globally, with active collaborations with global research institutions to facilitate immediate entry into new markets as they open</p>

1. Source: [Prohibition Partners Reports](#): the African Cannabis Report, the European Cannabis Report 3rd Edition, the LATAM Cannabis Report, the Oceania Cannabis Report

MGC Pharma is at forefront of Global Phyto-Cannabinoid based medicines

First product to Market



- █ CannEpiL™ is a Phyto-Cannabinoid based product used for **drug-resistant epilepsy**
- █ Being provided to patients in Australia via the **Authorised Prescriber Scheme** until registration is completed
- █ Price point and **efficacy** will make it a strong alternative to current medicines.

Research excellence



- █ Landmark collaboration agreement signed between **MGC, RMIT** and the **Hebrew University** to establish the **“CannaHub”**
- █ Establishing the **Cannabis Medicine Library**, and focusing on pre-clinical research on melanoma and prostate cancer
- █ Currently developing **CannEpiL™ App** for patient monitoring

Best-in class manufacturing




- █ **EU GMP certification** granted for the production and compounding of Phyto-cannabinoid based Investigational Medicinal Products (IMP)
- █ MGC Facilities are **unique** in Europe, allowing the development of further Phyto-Cannabinoids based medications and API
- █ **SME approval** by The **European Medicines Agency (EMA)**, for Scientific advice and fees incentives

Education and Patient access



- █ Strategic Alliance with Australia’s leading Epilepsy association, **Epilepsy Action Australia (EAA)**
- █ MGC products will be introduced by EAA to members in accordance with medical requirements
- █ Collaboration on developing **C4E campaign** to increase awareness and access to Cannabis based medicines



CannEpil™

The EU and AUS market for epilepsy is estimated to be ~500,000 patients¹

- ✔ Authorised by the TGA to **prescribe in Australia**
- ✔ **Phase III** submission in Australia (TGA)
- ✔ **Phase IIB** submission in Europe (EMA)
- ✔ Over **500k patients** in Europe and Australia
- ✔ Clinical observations on **160 patients** over 3 years, show **reduction of 50%** seizures in over 45% of the patients

CannEpil™ is MGC's first pharmaceutical-grade product targeting drug resistant (refractory) epilepsy, which accounts for approximately 30% of people diagnosed with epilepsy.

CogniCann™

The EU and AUS market for Dementia is estimated to be ~2,500,000 patients²

- ✔ **Phase IIB** submission in Australia (TGA)
- ✔ Over **2.5m patients** in Europe and Australia
- ✔ Clinical observations on **1,000 patients** over 3 years, show **improvement of quality of life** of the patients

CogniCann™ is MGC's pharmaceutical-grade product designed to improve Dementia and Alzheimer patients quality of life.

InCann™

The EU and AUS market for Chron's disease is estimated to be ~1,090,000 patients³

- ✔ **Phase III** submission in Europe (EMA)
- ✔ Over **1m patients** across Europe and Australia
- ✔ Clinical observations on **500 patients** over 3 years, show **improvement in CDAI scores**

InCann™ is MGC's pharmaceutical-grade BiActive slow release capsule targeted for Crohn's Disease and IBS



1. Source: [Epilepsy Action Australia](#) and [Epilepsy Alliance Europe](#)
 2. Source: [Health Direct](#) and [Alzheimer's Disease International](#)
 3. Source: [Crohn's & Colitis Australia](#) and [European Medicines Agency](#)

MGC Pharma is developing pharmaceutical grade products that leverage it's proprietary medical cannabis formula through successful clinical trials in Europe, Australia and Israel.

This will enable future medical product sales across the EU, Australia and other geographies, following the requisite legal and regulatory approvals.

Oncological & Cancer Side Effects

Tetrinol™ Treatment of Anorexia Cachexia in Cancer Patients

MXOT02GB01 Treatment of Glioblastoma (NIB)

MXOT02ME01 Treatment of Melanoma Cancer (RMIT/CannaHUB)

MXOT02PC01 Treatment of Prostate Cancer (RMIT/CannaHUB)

Preclinical in progress

Autoimmune Disease - Inflammatory

TopiCann™ Topical Treatment of Eczema and inflamed skin (RMIT/CannaHUB)

Preclinical results: Reduction 70% in 4 w.

MXAI01AB01 Anti Bacterial topical cream (RMIT/CannaHUB)

Preclinical in progress

Q2 2016

R&D Division established

- Establishing research program
- Building the Scientific advisory board - capitalizing 10 years of experience in the field

Q1 2017

Pre-Clinical program initiated

- Collecting clinical data from doctors and academics
- Design the protocols for the first product to market - CannEpil

Q3 2018

EU GMP approved

- First of its kind in the EU - cannabinoid compounding facility was approved to produce Cannabinoid based medications

Q4 2018

Authorised Prescribers initiated

- First IMP CannEpil has been Authorised for prescription by the TGA in Australia for Drug Resident Epilepsy

Q1 2019

EMA SME Qualification approved

- This allows MGC to apply for scientific advice, drug evaluation and registration of products with up to 100% reduction in fees

**Multiple cultivation sites to meet increasing global demand
Research into breeding and genetics driven with leading institutions and Universities**

**Greenhouse facility
in Czech Republic
+1,000m²**

Second cycle of Panax harvested, yielding over 700kg of high CBD and THC flowers

Biomass will be processed into CBD crystals for use in the Company's MGC Pharma product lines



**Open Field Farm and
Collaborative Partnerships
in Slovenia +4,000m²**

Genetic research program underway to isolate strains with specific levels cannabinoids for integration into the Company's R&D and product pipeline.

+4,000m² open field Hemp cultivation for raw materials



**Collaborative Partnerships
in Slovenia**

University of Ljubljana

Genetic research program underway to create genetic strains with high levels of CBD and THC for the treatment of specific disease symptoms.

Medicinal cannabis seeds planted in June 2017 for the project.

IHPS

The Slovenian Institute of Hop Research and Brewing

Collaboration with IHPS, Ljubljana, to cultivate strains for global export.



University of Ljubljana
Biotechnical Faculty

Maltese Government has granted MGC a contract for a large GMP manufacturing and cultivation facility Will provide cost-effective production and medicine, and direct access to the EU

MGC Pharma signs contract for full medical cannabis facility

The licence is subject to final legislative changes and presidential sign off that will permit the cultivation, production and commercialisation of medical cannabis and pharmaceutical grade medicines in Malta.

First federal bill on legalising medicinal cannabis in Malta passed in parliament during March 2018, and second bill passed on 16 April 2018.



*MGC CZ Facility

*Illustration

Medical Cannabis legalised in Malta – provides direct access to the EU

Malta is highly strategic towards the completion of the Company's EU focused business plan and operations.

Climate is ideal for cannabis cultivation which will allow 3 crops per year.

As part of the EU, Malta is attractive for establishing large scale operations.

- 🌿 MGC will establish turnkey “**seed to pharma**” state-of-the-art EU GMP production facility to provide its medicines globally
- 🌿 Increased site to 6,000m² with a multi-story facility that includes a cultivation area of 5,000m² and production area of 5,000m²
- 🌿 Access to existing operational and distribution pipelines in Europe and Australia
- 🌿 Direct access to key emerging UK/EU countries through the FDA Mutual Recognition agreement signed with Austria, Croatia, France, Italy, Malta, Spain, Sweden and the UK

Establishing a fully-vertically integrated medical cannabis ‘Seed to Pharma’ operation in the EU

6,000m² Site for a Maltese Medical Cannabis Production Facility

Research

- Clinical research hub with the Malta Medical Cannabis Hub
- Pharmaceutical research into new medications utilising the benefits of Phyto-Cannabinoids

Greenhouse Facility

- Cultivation in greenhouse facility producing up to 3 crops p.a
- Full production capacity of approx. 3.6 tonnes of biomass annually
- Highly cost effective cultivation due to Mediterranean climate

GMP Production and Manufacturing Facility

- Production of pharmaceutical grade whole plant extracts from MGC’s unique genetics
- Production of final medicines for specific indications such as CannEpiTM
- Production of Active Pharmaceutical Ingredients (API) for third parties compounding medications

- EU market estimate the production costs of raw materials to be a minimum of 1.2euro/gr
- More than 20% of EU production costs dedicated to energy and lights to compensate for adverse climate
- Malta’s climate is ideal for production with average yearly temperature of 23°C, lower energy costs to EU
- Malta provides large business incentives for the pharmaceutical industry

EU/UK
US\$115bn market by 2028¹



Germany is one of the key EU markets that is at the forefront of leading the commercialisation of the industry in Europe.

Current size of the German MC market is estimated as US\$16bn² and can be supplied by MGC’s Malta operation.

1. Source: [Prohibition Partners Report](#): the European Cannabis Report 3rd Edition
 2. Source: [Prohibition Partners Report](#): the European Cannabis Report 3rd Edition

Extensive network in place providing access to hospitals, pharmacies and research institutions around the world



Supply Agreement signed with Australian Pharmaceutical Distributor

Will bring first medical cannabis medicine, CannEpi™, to the Australian market

Targeting +70,000 Australians suffering from drug-resistant epilepsy

Supply agreement with NUBU Pharmaceuticals, a New Zealand based company, to supply MGC products into pharmacies, hospitals and universities throughout the country

This agreement provides a clear pathway for the delivery of the first MGC pharmaceutical products to patients via NUBU Pharma's partner Pro Pharma and its relationship with over 250 pharmacists in New Zealand

Supply & Distribution Agreement signed with European Pharmaceutical Company

MXC will supply medicinal cannabis flower products and CannEpi™

Founded in 2008, Lenis specialises in unlicensed medicines and niche therapeutic areas

Distributor of Gilead Sciences, Inc

Supply & Distribution Agreement signed with European Pharmaceutical Company

The agreement provides distribution rights into Malta, Italy, France, Spain Portugal, the Middle East and North Africa and the UK

Founded in 1978, AM MANGION has grown into a top ranking healthcare company

Distributor of Gilead Sciences, Inc

Exclusive distribution deal for Active Pharmaceutical Ingredients (API) grade extracts with leading laboratory equipment supplier Mikro+Polo

Slovenia's largest supplier of laboratory equipment, chemicals and diagnostics to established customer base of laboratories in Slovenia, Croatia and Bosnia

Emerging from a pharmaceutical grade pipeline, MGC Nutraceuticals provides premium Cannabis Sativa L. (Hemp) based CBD products that create balance and wellness

Pharmaceutical Grade Nutraceuticals & Product Formulation

Promoting inner health and wellbeing, MGC Nutraceuticals' product range includes multiple premium products, comprising of supplements and food grade products in flavours such as forrest fruit, blueberry and vanilla.

The products contain high grade Phyto-Cannabinoids which have been grown, extracted and processed under the Company's strict quality control guidelines and standards, alongside natural vegan proteins and vitamins.



Mabsut Life, a multi-year binding agreement to supply CBD extract to European distributor, operating in Germany, the Czech Republic and Austria




all natural vegan non gmo gluten free sugar free lactose free cruelty free

MGC Nutraceuticals

eCommerce website live.

To coincide with the launch, the release of a new product catalogue and new e-commerce website supporting the MGC Nutraceuticals range is now live.



Visit <https://www.mgcnutraceuticals.com/>

\$561Bn USD
global nutraceuticals market by 2023¹

1. Source: Mordor Intelligence Report: Nutraceuticals Market Size - Segmented By Type

mgc pharma 

www.mgcpharma.com.au